David Dalgarno - Feb 18, 2022 Form 4 Insider Report for Theseus Pharmaceuticals, Inc. (THRX)

Role
Chief Technical Officer
Signature
/s/ Bradford Dahms - Attorney-in-Fact
Stock symbol
THRX
Transactions as of
Feb 18, 2022
Transactions value $
$0
Form type
4
Date filed
2/23/2022, 07:00 PM
Previous filing
Oct 6, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction THRX Stock Option (right to buy) Award $0 +130K $0.00 130K Feb 18, 2022 Common Stock 130K $11.21 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 25% of the options vesting on February 18, 2023 and 1/48th of the options vesting monthly thereafter, subject to the Reporting Person's continuous service with the issuer.